Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges
Authors:
Top Cited Papers
Open Access
- 26 February 2026
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 394 (9) , 858-871
Abstract
Randomized trials of long-acting injectable antiretroviral therapy (ART) in persons with human immunodeficiency virus (HIV) who face challenges with adherence to oral medication are lacking. We conducted an open-label, randomized trial involving persons with HIV who had inadequate adherence to ART (a persistent HIV-1 RNA level of >200 copies per milliliter or loss to follow-up). Participants received up to 24 weeks of adherence support, conditional economic incentives, and standard care with oral ART (step 1). Participants who had an HIV-1 RNA level of 200 copies per milliliter or lower in step 1 were randomly assigned in a 1:1 ratio to either continue standard care or switch to monthly injections of long-acting cabotegravir plus rilpivirine with or without oral lead-in therapy (step 2). The primary outcome was regimen failure, defined as confirmed virologic failure (two consecutive HIV-1 RNA measurements of >200 copies per milliliter) or treatment discontinuation during step 2. In step 1 of the trial, we enrolled 453 participants; the median age was 40 years, 63% were Black, and 29% had been assigned female sex at birth. In step 2, a total of 306 participants underwent randomization; 152 were assigned to receive cabotegravir-rilpivirine and 154 to receive standard care. Step 2 randomization was stopped early on the basis of the superiority of cabotegravir-rilpivirine to standard care in secondary outcomes at a prespecified analysis performed after a median follow-up of 48 weeks. The cumulative incidence of regimen failure by week 48 was 22.8% in the cabotegravir-rilpivirine group and 41.2% in the standard-care group (difference, -18.4 percentage points; 98.4% confidence interval [CI], -32.4 to -4.3; P = 0.002). The cumulative incidence of an adverse event was 43.5% in the cabotegravir-rilpivirine group and 42.4% in the standard-care group (difference, 1.1 percentage points; 95% CI, -12.7 to 15.0). Resistance-associated mutations developed in 2 participants with confirmed virologic failure in each group. Monthly injections of long-acting cabotegravir-rilpivirine were superior to standard oral ART in reducing the risk of regimen failure among persons with HIV who had adherence challenges. (Funded by the National Institute of Allergy and Infectious Diseases; LATITUDE ClinicalTrials.gov number, NCT03635788.).Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (UM1 AI068634, UM1 AI068636, UM1 AI106701)
This publication has 18 references indexed in Scilit:
- Social Determinants of Health and Care Outcomes Among People With HIV in the United StatesOpen Forum Infectious Diseases, 2021
- Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAIDS, 2021
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyThe Lancet, 2020
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionNew England Journal of Medicine, 2020
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionNew England Journal of Medicine, 2020
- Conditional economic incentives to improve HIV prevention and treatment in low-income and middle-income countriesThe Lancet HIV, 2019
- Integrating Financial Incentives for Viral Load Suppression into HIV Care Coordination Programs: Considerations for Development and ImplementationJournal of Public Health Management & Practice, 2019
- Incentives for Viral Suppression in People Living with HIV: A Randomized Clinical TrialAIDS and Behavior, 2019
- Ending the HIV EpidemicJAMA, 2019
- Antiretroviral Therapy for the Prevention of HIV-1 TransmissionNew England Journal of Medicine, 2016